The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.
1. Emmaus Life Sciences Inc. (EMMA)
Emmaus Life Sciences, formerly known as MYnd Analytics Inc., is a commercial-stage biopharmaceutical company.
Lost 38.31% to close Tuesday’s (Sep.10) trading at $2.77.
News: Emmaus common stock and warrants will be delisted from The Nasdaq Stock Market at the start of trading on Wednesday, September 11, 2019.
The Company is not compliant with the $5 million minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1)) as well the 400 minimum Round Lot holder requirement under Nasdaq Listing Rule 5515(a)(1).
2. Protagonist Therapeutics Inc. (PTGX)
Protagonist Therapeutics is a clinical stage biopharmaceutical company.
Lost 38.31% to close Tuesday’s trading at $2.77.
News: No news
Clinical Trials & Near-term Catalysts:
— A phase II study of PTG-300, an injectable hepcidin mimetic, in the treatment of patients with transfusion-dependent as well as non-transfusion dependent beta-thalassemia, dubbed TRANSCEND, is underway, with initial results expected in the fourth quarter of 2019, and final topline data expected in the first half of 2020.
— A phase II study of PTG-300 in polycythemia vera is expected to begin in the third quarter of 2019.
— A phase II study of PTG-300 in hereditary hemochromatosis and an investigator-sponsored trial PTG-300 in patients with myelodysplastic syndromes are planned for early 2020.
— A global phase II clinical study of PTG-200 in Crohn’s disease is expected to be initiated in the fourth quarter of 2019.
— A phase II study of PN-943 in patients with ulcerative colitis is expected to be initiated in early 2020.
3. Stoke Therapeutics Inc. (STOK)
Stoke Therapeutics Inc is an early-stage biopharmaceutical company developing antisense oligonucleotide medicines for genetic diseases affecting the central nervous system, eye, liver, and kidney.
Lost 13.98% to close Tuesday’s trading at $28.80.